<DOC>
	<DOCNO>NCT02712203</DOCNO>
	<brief_summary>Healthy child receive two dos GlaxoSmithKline ( GSK ) Biologicals ' live attenuate measles-mumps-rubella vaccine ( MMR ) measles-mumps-rubella-varicella vaccine ( MMRV ) second year life.The purpose study assess effect age administration first dose reactogenicity immunogenicity measles component vaccine . In addition , study evaluate effect age first dose modified type vaccine administer .</brief_summary>
	<brief_title>MMR MMRV Vaccines : Effect Age First Dose Safety Immunogenicity Measles Component .</brief_title>
	<detailed_description />
	<mesh_term>Measles</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy male female subject 11 22 month time first vaccination . Written inform consent obtain parent/guardian subject . History previous measles , mumps , rubella and/or varicella vaccination disease know exposure disease within 30 day prior inclusion study . Any confirm suspected immunosuppressive immunodeficient condition , include chronic administration ( defined 14 day ) immunesuppressants immunemodifying drug within six month prior firs vaccine dose . History neurologic disorder seizure . History allergic disease reaction likely exacerbate component vaccine . Planned administration vaccine foreseen study protocol 30 day prior vaccination 4256 day vaccination</criteria>
	<gender>All</gender>
	<minimum_age>11 Months</minimum_age>
	<maximum_age>22 Months</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Measles vaccine</keyword>
	<keyword>Priorix</keyword>
	<keyword>Priorix-Tetra</keyword>
	<keyword>Age vaccination</keyword>
</DOC>